All In MedTech

Device Trial Radar · NCT06041945

Artificial Intelligence to Implement Cost-saving Strategies for Colonoscopy Screening Based on in Vivo Prediction of Polyp Histology

Saving by Artificial Intelligence for Virtual Endoscopy Biopsy Artificial Intelligence to Implement Cost-saving Strategies for Colonoscopy Screening Based on in Vivo Prediction of Polyp Histology

Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 1,800 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,800

Planned (sponsor's estimate)

Start

Sep 21, 2023

Primary completion

Sep 1, 2027

Study completion Sep 1, 2027

Sponsor

Lead sponsor
Istituto Clinico HumanitasAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 18, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated device
No
Who can join
All sexes, from 40 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This three parallel-arms, randomized, multicenter trial is aimed at investigating the value of AI-assisted optical biopsy for differentiating between neoplastic and non-neoplastic polyps which will lead to the implementation of cost-saving strategies in screening programs. A cost-effectiveness analyses with the use of modern trial emulation analyses of large observational and clinical trial datasets and real-cost data will be conducted. To improve personalized treatment with a novel colonoscopy CADx risk-prediction tool, the investigators will even develop a novel deep learning algorithm for the optical biopsy of the alternative pathway of colorectal cancer carcinogenesis, namely the serrated pathway and develop cost-effectiveness models of AI-assisted optical biopsy in colorectal cancer screening that provides reliable information to identify cancer risk regardless of physicians' skill.

Conditions

  • Colonic Neoplasms

Interventions

  • Standard, high-definition colonoscopy with the use of CADe assistanceDevice

    All detected polyps regardless of size and optical diagnosis will be resected and sent to pathology.

  • Standard, high-definition colonoscopy with the use of CADe/CADx assistance, no leave-in-situDevice

    All detected polyps regardless of size and optical diagnosis will be resected and sent to pathology.

  • Standard, high-definition colonoscopy with the use of CADe/CADx assistance, leave-in-situDevice

    Polyps will be left in situ if diminutive (≤5 mm) in size, located in the rectum or sigma and optically diagnosed by the endoscopist using the system to be hyperplastic with high confidence, otherwise resected and sent to pathology.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Non-inferiority in Adenoma Detection RateTime frame: 4 years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Istituto Clinico Humanitas

    Rozzano, Milano, Italy · Recruiting

  • Istituto Clinico Humanitas

    Rozzano, Milano, Italy · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.